Format
Sort by
Items per page

Send to

Choose Destination

Best matches for METHYLPHENIDATE/TU:

Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. Sugrue D et al. Am J Health Syst Pharm. (2014)

[The effect of methylphenidate on appetite and weight]. Bou Khalil R et al. Encephale. (2017)

Cotempla XR-ODT--another long-acting methylphenidate for ADHD. et al. Med Lett Drugs Ther. (2017)

Search results

Items: 1 to 20 of 4855

1.
2.

Pharmacotherapy for amphetamine dependence: A systematic review.

Lee NK, Jenner L, Harney A, Cameron J.

Drug Alcohol Depend. 2018 Oct 1;191:309-337. doi: 10.1016/j.drugalcdep.2018.06.038. Epub 2018 Aug 22. Review. Erratum in: Drug Alcohol Depend. 2018 Nov 1;192:238.

PMID:
30173086
3.

Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.

Teuscher NS, Sikes CR, McMahen R, Engelking D.

J Clin Psychopharmacol. 2018 Oct;38(5):467-474. doi: 10.1097/JCP.0000000000000944.

PMID:
30119076
4.

Case report: narcolepsy type 1 in an adolescent with HIV infection-coincidence or potential trigger?

Scherrer KS, Relly C, Hackenberg A, Berger C, Paioni P.

Medicine (Baltimore). 2018 Jul;97(30):e11490. doi: 10.1097/MD.0000000000011490.

5.

Neurocognitive assessment of children with neurodevelopmental disorders: Preliminary findings.

Kawabe K, Horiuchi F, Kondo S, Matsumoto M, Seo K, Oka Y, Ueno SI.

Pediatr Int. 2018 Sep;60(9):820-827. doi: 10.1111/ped.13662.

PMID:
30019794
6.

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.

Osland ST, Steeves TD, Pringsheim T.

Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990. doi: 10.1002/14651858.CD007990.pub3. Review.

PMID:
29944175
7.

Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder.

Sudnawa KK, Chirdkiatgumchai V, Ruangdaraganon N, Khongkhatithum C, Udomsubpayakul U, Jirayucharoensak S, Israsena P.

Pediatr Int. 2018 Sep;60(9):828-834. doi: 10.1111/ped.13641. Epub 2018 Sep 5.

PMID:
29931709
8.
9.

Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.

Frampton JE.

Drugs. 2018 Jul;78(10):1025-1036. doi: 10.1007/s40265-018-0936-0. Review.

PMID:
29923015
10.

Methylphenidate Induced Acute Dystonic Reaction.

Uzun ME, Korkmaz MF, Ekici A, Kaymaz N.

Indian J Pediatr. 2018 Jul;85(7):577. doi: 10.1007/s12098-018-2711-3. Epub 2018 May 23. No abstract available.

PMID:
29790008
11.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C.

Cochrane Database Syst Rev. 2018 May 9;5:CD012069. doi: 10.1002/14651858.CD012069.pub2. Review.

PMID:
29744873
12.

Pharmacological interventions for apathy in Alzheimer's disease.

Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL.

Cochrane Database Syst Rev. 2018 May 4;5:CD012197. doi: 10.1002/14651858.CD012197.pub2. Review.

PMID:
29727467
13.

Efficacy of Hippotherapy Versus Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Oh Y, Joung YS, Jang B, Yoo JH, Song J, Kim J, Kim K, Kim S, Lee J, Shin HY, Kwon JY, Kim YH, Jeong B.

J Altern Complement Med. 2018 May;24(5):463-471. doi: 10.1089/acm.2017.0358. Epub 2018 Apr 11.

PMID:
29641212
14.

[All you need to know about methylphenidate (and dared not ask)].

Zimmer L, Fourneret P.

Arch Pediatr. 2018 Apr;25(3):229-235. doi: 10.1016/j.arcped.2018.01.002. Epub 2018 Mar 12. French.

PMID:
29544968
15.

Treatment of Intermittent Explosive Disorder With Carbamazepine.

Coskun F, Akca OF.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):82-83. doi: 10.1097/WNF.0000000000000276. No abstract available.

PMID:
29533363
16.

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A; ICASA consensus group, Matthys F.

Eur Addict Res. 2018;24(1):43-51. doi: 10.1159/000487767. Epub 2018 Mar 6.

17.

QTc prolongation after ADHD medication.

Snircova E, Marcincakova Husarova V, Ondrejka I, Hrtanek I, Farsky I, Nosalova G.

Neuro Endocrinol Lett. 2018 Feb;38(8):549-554.

PMID:
29504733
18.

Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study.

Fife D, Cepeda MS, Baseman A, Richards H, Hu P, Starr HL, Sena AG.

PLoS One. 2018 Feb 28;13(2):e0193453. doi: 10.1371/journal.pone.0193453. eCollection 2018.

19.

Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats.

Loureiro-Vieira S, Costa VM, Duarte JA, Duarte-Araújo M, Gonçalves-Monteiro S, Maria de Lourdes B, Carvalho F, Capela JP.

Biomed Pharmacother. 2018 Apr;100:551-563. doi: 10.1016/j.biopha.2018.02.017. Epub 2018 Feb 23.

PMID:
29482048
20.

Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.

Stuhec M, Locatelli I.

Int J Clin Pharm. 2018 Apr;40(2):341-344. doi: 10.1007/s11096-018-0605-0. Epub 2018 Feb 21.

PMID:
29468526

Supplemental Content

Loading ...
Support Center